Modeling of molecular interaction between apoptin, BCR-Abl and CrKL - an alternative approach to conventional rational drug design

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Panigrahi, Soumya ^a   Stetefeld, Jörg ^b   Jangamreddy, Jaganmohan R ^g   Mandal, Soma ^c   Mandal, Sanat K ^d,e   Los, Marek ^f,g  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^e GIS Applications Specialist   (Canada)

^f BioApplications Enterprises Winnipeg   (Canada)

^g LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; APOPTIN; BCR ABL PROTEIN; CRK LIKE PROTEIN; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; AMINO ACID; CAPSID PROTEIN; NUCLEAR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; VP3 PROTEIN, CHICKEN ANEMIA VIRUS;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COMPUTER MODEL; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG DESIGN; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; GROWTH; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOLECULAR MODEL; PLASMID; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; QUANTITATIVE STRUCTURE PROPERTY RELATION; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SURVIVAL; AMINO ACID SEQUENCE; ANIMAL; BIOLOGY; CELL DEATH; CELL NUCLEUS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; HYDROGEN BOND; METABOLISM; MOLECULAR GENETICS; MOUSE; PHOSPHORYLATION; PROTEIN TRANSPORT; SEQUENCE ALIGNMENT; SRC HOMOLOGY DOMAIN; STRUCTURAL HOMOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; AMINO ACIDS; ANIMALS; CAPSID PROTEINS; CELL DEATH; CELL NUCLEUS; COMPUTATIONAL BIOLOGY; DOWN-REGULATION; DRUG DESIGN; FUSION PROTEINS, BCR-ABL; HUMANS; HYDROGEN BONDING; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN TRANSPORT; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS; STRUCTURAL HOMOLOGY, PROTEIN;

EID: 84855570062     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028395     Document Type: Article

References (74)

1. Pisabarro MT, Serrano L, Wilmanns M, (1998) Crystal structure of the abl-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions. JMolBiol 281: 513-521.
2. Quintas-Cardama A, Cortes J, (2009) Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113: 1619-1630.
3. Zhang J, Adrian FJ, Jahnke W, Cowan-Jacob SW, Li AG, et al. (2010) Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463: 501-506.
4. Peng C, Chen Y, Li D, Li S, (2010) Role of Pten in leukemia stem cells. Oncotarget 1: 155-160.
5. Chomel JC, Turhan AG, (2011) Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget 2: 713-727.
6. Schiffer CA, (2007) BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. NEnglJ Med 357: 258-265.
7. Schnaiter A, Stilgenbauer S, (2010) Refractory chronic lymphocytic leukemia-new therapeutic strategies. Oncotarget 1: 471-482.
8. Nagar B, Hantschel O, Seeliger M, Davies JM, Weis WI, et al. (2006) Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. MolCell 21: 787-798.
9. Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, et al. (2003) Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112: 859-871.
10. Koch CA, Anderson D, Moran MF, Ellis C, Pawson T, (1991) SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science 252: 668-674.
11. Pawson T, Schlessingert J, (1993) SH2 and SH3 domains. Curr Biol 3: 434-442.
12. Mandal S, Moudgil M, Mandal SK, (2009) Rational drug design. EurJPharmacol 625: 90-100.
13. Adair BM, (2000) Immunopathogenesis of chicken anemia virus infection. DevComp Immunol 24: 247-255.
14. Los M, Panigrahi S, Rashedi I, Mandal S, Stetefeld J, et al. (2009) Apoptin, a tumor-selective killer. BiochimBiophysActa 1793: 1335-1342.
15. Heilman DW, Teodoro JG, Green MR, (2006) Apoptin nucleocytoplasmic shuttling is required for cell type-specific localization, apoptosis, and recruitment of the anaphase-promoting complex/cyclosome to PML bodies. JVirol 80: 7535-7545.
16. Maddika S, Booy EP, Johar D, Gibson SB, Ghavami S, et al. (2005) Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway. JCell Sci 118: 4485-4493.
17. Maddika S, Mendoza FJ, Hauff K, Zamzow CR, Paranjothy T, et al. (2006) Cancer-selective therapy of the future: apoptin and its mechanism of action. Cancer BiolTher 5: 10-19.
18. Maddika S, Wiechec E, Ande SR, Poon IK, Fischer U, et al. (2008) Interaction with PI3-kinase contributes to the cytotoxic activity of apoptin. Oncogene 27: 3060-3065.
19. Poon IK, Oro C, Dias MM, Zhang J, Jans DA, (2005) Apoptin nuclear accumulation is modulated by a CRM1-recognized nuclear export signal that is active in normal but not in tumor cells. Cancer Res 65: 7059-7064.
20. Wagstaff KM, Jans DA, (2009) Nuclear drug delivery to target tumour cells. EurJPharmacol 625: 174-180.
21. Jiang J, Cole D, Westwood N, Macpherson L, Farzaneh F, et al. (2010) Crucial roles for protein kinase C isoforms in tumor-specific killing by apoptin. Cancer Res 70: 7242-7252.
22. Los M, Maddika S, Erb B, Schulze-Osthoff K, (2009) Switching Akt: from survival signaling to deadly response. Bioessays 31: 492-495.
23. Maddika S, Panigrahi S, Wiechec E, Wesselborg S, Fischer U, et al. (2009) Unscheduled Akt-triggered activation of cyclin-dependent kinase 2 as a key effector mechanism of apoptin's anticancer toxicity. MolCell Biol 29: 1235-1248.
24. nen-Van Oorschot AA, Zhang YH, Leliveld SR, Rohn JL, Seelen MC, et al. (2003) Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis. JBiolChem 278: 27729-27736.
25. Leliveld SR, Zhang YH, Rohn JL, Noteborn MH, Abrahams JP, (2003) Apoptin induces tumor-specific apoptosis as a globular multimer. JBiolChem 278: 9042-9051.
26. Rychlewski L, Zhang B, Godzik A, (1999) Functional insights from structural predictions: analysis of the Escherichia coli genome. Protein Sci 8: 614-624.
27. Ferraro E, Peluso D, Via A, Ausiello G, Helmer-Citterich M, (2007) SH3-Hunter: discovery of SH3 domain interaction sites in proteins. Nucleic Acids Res 35: W451-W454.
28. Ren R, Mayer BJ, Cicchetti P, Baltimore D, (1993) Identification of a ten-amino acid proline-rich SH3 binding site. Science 259: 1157-1161.
29. Lim WA, Richards FM, (1994) Critical residues in an SH3 domain from Sem-5 suggest a mechanism for proline-rich peptide recognition. NatStructBiol 1: 221-225.
30. Rohn JL, Zhang YH, Aalbers RI, Otto N, Den HJ, et al. (2002) A tumor-specific kinase activity regulates the viral death protein Apoptin. J Biol Chem 277: 50820-50827.
31. Mandal S, Davie JR, (2007) An integrated analysis of genes and pathways exhibiting metabolic differences between estrogen receptor positive breast cancer cells. BMCCancer 7: 181.
32. Dahlquist KD, Salomonis N, Vranizan K, Lawlor SC, Conklin BR, (2002) GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways. NatGenet 31: 19-20.
33. Doniger SW, Salomonis N, Dahlquist KD, Vranizan K, Lawlor SC, et al. (2003) MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data. Genome Biol 4: R7.
34. Ingenuity I, (2011) IPA (Ingenuity Pathway Analysis).
35. Feller SM, (2001) Crk family adaptors-signalling complex formation and biological roles. Oncogene 20: 6348-6371.
36. Maddika S, Bay GH, Kroczak TJ, Ande SR, Wiechec E, et al. (2007) Akt is transferred to the nucleus of cells treated with apoptin, and it participates in apoptin-induced cell death. Cell Prolif 40: 835-848.
37. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, et al. (2006) Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441: 523-527.
38. Chen CC, Hwang JK, Yang JM, (2006) (PS)2: protein structure prediction server. Nucleic Acids Res 34: W152-W157.
39. Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F, et al. (2000) Comparative protein structure modeling of genes and genomes. AnnuRevBiophysBiomolStruct 29: 291-325.
40. Guex N, Peitsch MC, (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18: 2714-2723.
41. Notredame C, Higgins DG, Heringa J, (2000) T-Coffee: A novel method for fast and accurate multiple sequence alignment. JMolBiol 302: 205-217.
42. Laskowski RA, (1993) pp. 283-291 In: MacArthur M W MDSTJM, editor.
43. Ramachandran GN, (1963) Protein Structure and Crystallography. Science 141: 288-291.
44. Ramachandran GN, Ramakrishnan C, Sasisekharan V, (1963) Stereochemistry of polypeptide chain configurations. J MolBiol 7: 95-99.
45. Comeau SR, Gatchell DW, Vajda S, Camacho CJ, (2004) ClusPro: an automated docking and discrimination method for the prediction of protein complexes. Bioinformatics 20: 45-50.
46. Fujitsu l. Scigress Explorer Ultra 2008.
47. Kozakov D, Hall DR, Beglov D, Brenke R, Comeau SR, et al. (2010) Achieving reliability and high accuracy in automated protein docking: ClusPro, PIPER, SDU, and stability analysis in CAPRI rounds 13-19. Proteins 78: 3124-3130.
48. Ritchie DW, Venkatraman V, (2010) Ultra-fast FFT protein docking on graphics processors. Bioinformatics 26: 2398-2405.
49. Sigrist CJ, Cerutti L, de CE, Langendijk-Genevaux PS, Bulliard V, et al. (2010) PROSITE, a protein domain database for functional characterization and annotation. Nucleic Acids Res 38: D161-D166.
50. Kardinal C, Konkol B, Lin H, Eulitz M, Schmidt EK, et al. (2001) Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes. Blood 98: 1773-1781.
51. Hazlehurst LA, Bewry NN, Nair RR, Pinilla-Ibarz J, (2009) Signaling networks associated with BCR-ABL-dependent transformation. Cancer Control 16: 100-107.
52. Pear WS, Miller JP, Xu L, Pui JC, Soffer B, et al. (1998) Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92: 3780-3792.
53. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, et al. (1994) Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 13: 764-773.
54. Samanta A, Perazzona B, Chakraborty S, Sun X, Modi H, et al. (2011) Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. Leukemia 25: 463-472.
55. Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, et al. (2002) Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1: 479-492.
56. Coppo P, Flamant S, De MV, Jarrier P, Guillier M, et al. (2006) BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. BrJHaematol 134: 171-179.
57. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, et al. (2004) JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18: 189-218.
58. Ilaria RL Jr, Hawley RG, Van Etten RA, (1999) Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood 93: 4154-4166.
59. Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, et al. (2002) The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 21: 5766-5774.
60. Workman P, (2004) Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. BiochemSocTrans 32: 393-396.
61. Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, et al. (1996) The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway. Oncogene 12: 839-846.
62. Posern G, Rapp UR, Feller SM, (2000) The Crk signaling pathway contributes to the bombesin-induced activation of the small GTPase Rap1 in Swiss 3T3 cells. Oncogene 19: 6361-6368.
63. Meyer J, Jucker M, Ostertag W, Stocking C, (1998) Carboxyl-truncated STAT5beta is generated by a nucleus-associated serine protease in early hematopoietic progenitors. Blood 91: 1901-1908.
64. Nam HJ, Haser WG, Roberts TM, Frederick CA, (1996) Intramolecular interactions of the regulatory domains of the Bcr-Abl kinase reveal a novel control mechanism. Structure 4: 1105-1114.
65. Sawyers CL, Callahan W, Witte ON, (1992) Dominant negative MYC blocks transformation by ABL oncogenes. Cell 70: 901-910.
66. Frisch MJ, Trucks GW, Schlegel HB, et al. (2004) Gaussian 03, Revision C.02, Gaussian, Inc., Wallingford CT.
67. Hallek M, nhauser-Riedl S, Herbst R, Warmuth M, Winkler A, et al. (1996) Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. BrJ Haematol 94: 5-16.
68. Klein E, Ben-Bassat H, Neumann H, Ralph P, Zeuthen J, et al. (1976) Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. IntJ Cancer 18: 421-431.
69. Lozzio CB, Lozzio BB, (1975) Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45: 321-334.
70. Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, et al. (1999) Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J ExpMed 189: 1229-1242.
71. Ghavami S, Eshraghi M, Kadkhoda K, Mutawe MM, Maddika S, et al. (2009) Role of BNIP3 in TNF-induced cell death-TNF upregulates BNIP3 expression. Biochim Biophys Acta 1793: 546-560.
72. Ghavami S, Eshragi M, Ande SR, Chazin WJ, Klonisch T, et al. (2010) S100A8/A9 induces autophagy and apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes that involves BNIP3. Cell Res 20: 314-331.
73. Ghavami S, Mutawe MM, Hauff K, Stelmack GL, Schaafsma D, et al. (2010) Statin-triggered cell death in primary human lung mesenchymal cells involves p53-PUMA and release of Smac and Omi but not cytochrome c. BiochimBiophys Acta 1803 pp. 452-467.
74. Ghavami S, Mutawe MM, Sharma P, Yeganeh B, McNeill KD, et al. (2011) Mevalonate cascade regulation of airway mesenchymal cell autophagy and apoptosis: a dual role for p53. PLoS One 6: e16523.